Characterization of microRNA expression in serous ovarian carcinoma

International Journal of Molecular Medicine

Volumn 34, Issue 2, 2014, Pages 491-498

  Li, Yanhong ^a   Yao, Li ^a   Liu, Fei ^a   Hong, Jia ^a   Chen, Lin ^a   Zhang, Beilei ^a   Zhang, Wei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Microarray; MicroRNA; Ovarian cancer

Indexed keywords

MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; OVIDUCT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROUS OVARIAN CARCINOMA; BIOSYNTHESIS; CYSTADENOCARCINOMA; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84904251384     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1813     Document Type: Article

References (44)

1. Permuth-Wey J and Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol 472: 413-437, 2009.
2. Seidman JD and Kurman RJ: Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 17: 909-925, vii, 2003.
3. Shih IeM and Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518, 2004.
4. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ and Ronnett BM: The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23: 41-44, 2004. (Pubitemid 38018236)
5. Levanon K, Crum C and Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293, 2008.
6. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
7. Wang F, Niu G, Chen X and Cao F: Molecular imaging of microRNAs. Eur J Nucl Med Mol Imaging 38: 1572-1579, 2011.
8. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
9. Wang F, Fu XD, Zhou Y and Zhang Y: Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep 42: 725-730, 2009.
10. Wang F, Song X, Li X, et al: Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS One 8: e61792, 2013.
11. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59, 2009.
12. Yu SL, Chen HY, Chang GC, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57, 2008.
13. Zaman MS, Maher DM, Khan S, Jaggi M and Chauhan SC: Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 5: 44, 2012.
14. Zhang L, Volinia S, Bonome T, et al: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105: 7004-7009, 2008. (Pubitemid 351754520)
15. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007. (Pubitemid 47437445)
16. Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
17. Gallagher MF, Flavin RJ, Elbaruni SA, et al: Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients. J Ovarian Res 2: 19, 2009.
18. Wyman SK, Parkin RK, Mitchell PS, et al: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4: e5311, 2009.
19. Laios A, O'Toole S, Flavin R, et al: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35, 2008.
20. Eitan R, Kushnir M, Lithwick-Yanai G, et al: Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 114: 253-259, 2009.
21. Yang N, Kaur S, Volinia S, et al: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68: 10307-10314, 2008.
22. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B and Canevari S: Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 42: 1262-1272, 2010.
23. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P and Calin GA: Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res 717: 77-84, 2011.
24. Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li T: miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37: D105-D110, 2009.
25. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
26. Vlachos IS, Kostoulas N, Vergoulis T, et al: DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 40: W498-W504, 2012.
27. Suh KS, Park SW, Castro A, et al: Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 10: 1069-1083, 2010.
28. Kriplani D and Patel MM: Immunohistochemistry: a diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary. South Asian J Cancer 2: 254-258, 2013.
29. Muraoka T, Soh J, Toyooka S, et al: The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer 82: 485-490, 2013.
30. Nadal E, Chen G, Gallegos M, et al: Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res 19: 6842-6852, 2013.
31. Suzuki R, Yamamoto E, Nojima M, et al: Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol: Aug 13, 2013 (Epub ahead of print).
32. He XX, Chang Y, Meng FY, et al: MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 31: 3357-3369, 2012.
33. Kong KL, Kwong DL, Chan TH, et al: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61: 33-42, 2012.
34. Fu X, Han Y, Wu Y, et al: Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 41: 1245-1253, 2011.
35. Yu X, Song H, Xia T, et al: Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene 532: 87-93, 2013.
36. Karaayvaz M, Zhai H and Ju J: miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis 4: e659, 2013.
37. Liu Y, Hei Y, Shu Q, et al: VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One 7: e35800, 2012.
38. Bray I, Tivnan A, Bryan K, et al: MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303: 56-64, 2011.
39. Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K and Inazawa J: The impact of mirna-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res 12: 58-68, 2014.
40. Wu K, Hu G, He X, et al: MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathol Oncol Res 19: 739-748, 2013.
41. Liang LH and He XH: Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin 32: 1311-1320, 2011.
42. Makker A, Goel MM, Das V and Agarwal A: PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update. Gynecol Endocrinol 28: 175-181, 2012.
43. Nilsson EE and Skinner MK: Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod Biomed Online 5: 254-258, 2002.
44. Slaby O, Svoboda M, Fabian P, et al: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402, 2007. (Pubitemid 351238155)